An Open-Label Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution 0.002% in Latanoprost Low/Non-Responder Subjects Diagnosed with Primary Open-angle Glaucoma or Ocular Hypertension - Spectrum 5 Study
Brief description of study
The purpose of this research study is to see how well the investigational study drug (eye drop) will work in subjects diagnosed with Primary Open-Angle Glaucoma (POAG) or Ocular (“Ocular” means “eye”) Hypertension (high internal pressure) (OHT) who do not have enough IOP lowering with latanoprost. “Investigational” means the study drug is currently being tested for the purpose of this study. The study drug being tested has not been approved for sale or use by the United States Food and Drug Administration (FDA). Santen is the sponsor (company paying for this study) of this clinical study.
Clinical Study Identifier: s19-02003
ClinicalTrials.gov Identifier: NCT03697811
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
